Gilead to buy cancer drug developer Arcellx for up to $7.8bn
- Posted on February 23, 2026
- By Financial Times
- 6 Views
Gilead to buy cancer drug developer Arcellx for up to $7.8bn
Deal comes as pharmaceutical groups rush to acquire smaller biotech firms with proven drug pipelines
